# ORIGINAL ARTICLE

# Enhanced Expression of Dopamine D<sub>1</sub> and Glutamate NMDA Receptors in Dopamine D<sub>4</sub> Receptor Knockout Mice

Lu Gan,<sup>1</sup> Tomas L. Falzone,<sup>2</sup> Kehong Zhang,<sup>1</sup> Marcelo Rubinstein,<sup>2</sup> Ross J. Baldessarini,<sup>1</sup> and Frank I. Tarazi\*,<sup>1</sup>

<sup>1</sup>Mailman Research Center, McLean Division of Massachusetts General Hospital, Belmont, MA 02478; Department of Psychiatry and Neuroscience Program, Harvard Medical School; Boston, MA 02115; and <sup>2</sup>Instituto de Investigaciones en Ingeniería Genética y Biología Molecular (CONICET), Universidad de Buenos Aires, Buenos Aires, Argentina

Received July 29, 2003; Accepted August 24, 2003

#### **Abstract**

Expression of dopamine ([DA]  $D_1$  and  $D_2$ ) and glutamate ([Glu], (N-methyl-D-aspartic acid [NMDA],  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid [AMPA], and kanaic acid [KA]) receptor types were analyzed autoradiographically in forebrain regions of  $D_4$  receptor knockout mice and their wild-type controls. Selective radioligand binding to  $D_4$  receptors was virtually absent in  $D_4$  receptor knockout mouse brain in contrast to significant specific  $D_4$  binding in forebrain tissue of wild-type controls. Labeling of  $D_1$  receptors was significantly increased in nucleus accumbens (NAc; 39%) and caudate putamen (CPu; 42%) of  $D_4$ -knockout mice vs wild-type controls. In addition, NMDA receptor labeling was significantly increased in NAc (31%), CPu (40%), and hippocampal  $CA_1$  (21%) and  $CA_3$  (25%) regions of  $D_4$  knockouts vs wild-type controls. No changes in  $D_2$ , AMPA or KA receptors were found. The findings suggest that  $D_1$ ,  $D_4$ , and NMDA receptors might interact functionally and that developmental absence of  $D_4$  receptors might trigger compensatory mechanisms that enhance expression of  $D_1$  receptors in NAc and CPu, and NMDA receptors in NAc, CPu, and hippocampus. The findings also encourage cautious interpretation of results in knockout mice with targeted absence of specific genes, as complex adaptive changes not directly related to the missing gene might contribute to physiological and behavioral responses.

**Index Entries:** Autoradiography; caudate putamen; dopamine receptors; D<sub>4</sub>-receptor; genetic knockout; glutamate receptors; mutant mice.

### Introduction

Dopamine (DA)  $D_4$  receptors are members of the  $D_2$ -like receptor family, which also includes  $D_2$  and  $D_3$  receptors. Other well-characterized DA receptors ( $D_1$ ,  $D_5$ ) constitute the  $D_1$ -like family. Members of each family share similar molecular structures and

pharmacological profiles but differ greatly in relative abundance and neuroanatomical distribution (Baldessarini and Tarazi, 1996; Neve and Neve, 1997).

Several functional activities have been ascribed to D<sub>4</sub> receptor stimulation, including inhibition of adenylyl cyclase activity, activation of arachidonic acid release, blockade of L-type calcium currents,

<sup>\*</sup>Author to whom all correspondence and reprint requests should be addressed. E-mail: ftarazi@hms.harvard.edu

and stimulation of membrane phospholipid methylation in cultured neuroblastoma cell lines (see Tarazi and Baldessarini, 1999a). Human D<sub>4</sub> receptors can be transcribed into polymorphic variants that differ in the number of repeats of a 48-amino-acid sequence within the functionally critical third intracellular loop of the peptide. There can be 2–11 repeats, but those with 2, 4, or 7, designated as  $D_{4.2}$ ,  $D_{4.4}$ , or  $D_{4.7}$ , are the most prevalent human alleles (Van Tol et al., 1992; Lichter et al., 1993). Clinical genetic studies have associated D₄ receptor polymorphism with specific behavioral traits, including novelty seeking (Benjamin et al., 1996; Ebstein et al., 1996), and with attention deficit-hyperactivity disorder (La Hoste et al., 1996; Swanson et al., 1998). In addition, behavioral neuropharmacological findings link D₄ receptors to hyperactivity in juvenile rats with neonatal lesions of DA neurons (Zhang et al., 2001, 2002).

Immunohistochemical and binding studies indicate that cerebral  $D_4$  receptors are highly expressed in cerebral cortical regions and also in hippocampal formation, including the subiculum (Van Tol et al., 1991; Ariano et al., 1997; Tarazi et al., 1997a). In prefrontal cortex,  $D_4$  receptors are expressed in both inhibitory  $\gamma$ -aminobutyric acid (GABA) interneurons and excitatory glutamate (Glu) pyramidal neurons where they function as inhibitory modulators of Glu neurotransmission (Mrzljak et al., 1996; Rubinstein et al., 2001). Lower, but still significant, levels of  $D_4$  receptors are also expressed in caudate putamen (CPu) and nucleus accumbens (NAc) (Defagot et al., 1997; Tarazi et al., 1997a, 1998).

Mice with targeted gene depletion of  $D_4$  receptors have been generated using recombinant DNA technologies in embryonic stem cells (Rubinstein et al., 1997). These D₄ receptor-lacking mutant mice displayed distinct behaviors compared to wild-type mice, including increased locomotor sensitivity to ethanol, cocaine, and methamphetamine (Rubinstein et al., 1997), reduced exploration of novel stimuli (Dulawa et al., 1999), and enhanced reactivity to unconditioned fear (Falzone et al., 2002). Biochemical and physiological analyses revealed that D<sub>4</sub> knockout mice had higher rates of DA metabolic turnover in dorsal striatum (Rubinstein et al., 1997) and increased excitability of Glu neurons in cerebral cortex (Rubinstein et al., 2001). Therefore, D<sub>4</sub> receptor mutant mice might constitute important neurobiological resources to examine the functions of D<sub>4</sub> receptors and related behaviors. However, these findings should be interpreted carefully, as phenotypic variability, genetic background, and developmental compensatory mechanisms might influence functions and behaviors associated with the absence of specific genes (Bucan and Abel, 2002).

Despite extensive behavioral characterization of D<sub>4</sub> receptor mutant mice (Rubinstein et al., 1997; Dulawa et al., 1999; Falzone et al., 2002), molecular effects of D<sub>4</sub> receptor depletion on concentrations of other DA receptors have not been well defined or compared quantitatively to wild-type mice expressing normal levels of cerebral  $D_4$  receptors. In addition, close functional and often antagonistic interactions between DA and Glu systems (Carlsson and Carlsson, 1990; Carlsson et al., 2001) suggest that knocking out D<sub>4</sub> receptors might trigger changes in Glu receptors. Accordingly, we applied quantitative in vitro receptor autoradiography to assess regulation of DA D<sub>1</sub> and D<sub>2</sub> receptors, as well as the three ionotropic Glu receptors (N-methyl-D-aspartic acid [NMDA],  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainic acid (KA) types) in forebrain regions of D<sub>4</sub> receptor mutant mice vs wild-type controls.

### **Materials and Methods**

### Materials

Radiochemicals from New England Nuclear–Perkin-Elmer (Boston, MA) were DA receptor ligands, [N-methyl-³H]R,S-nemonapride (86 Ci/mmol for D<sub>2</sub>/D<sub>4</sub> receptors) and [N-methyl-³H]SCH-23390 (81 Ci/mmol for D<sub>1</sub> receptors); and Glu receptor ligands, [3-³H](+)-5-methyl-10,11-dihydro-[5H]-dibenzo(a,d)cyclohepten-5,10-imine (MK-801; 24 Ci/mmol for NMDA receptors), [5-³H]AMPA (83 Ci/mmol for AMPA receptors), and [vinylidene-³H]KA (58 Ci/mmol for KA receptors). Tritium autoradiography standards were from Amersham (Arlington Heights, IL). Tritium-sensitive Hyperfilm, as well as D-19 developer and fixative for autoradiography were from Eastman-Kodak (Rochester, NY).

Chemicals and drugs included 6-cyano-7-nitroquinoxaline (CNQX), 1,3-ditolylguanidine (DTG), cis-flupenthixol dihydrochloride, KA, ketamine hydrochloride, pindolol, potassium thiocyanate (KSCN), S(-)-raclopride, S(-)-sulpiride, and spermine tetrahydrochloride, all obtained from Sigma–Research Biochemicals International (Sigma–RBI; Natick, MA); ethylene diamine tetra-acetic acid (EDTA) from Fisher Scientific (Fairlawn, NJ), as well as L-glutamic acid (Glu), L-glycine hydrochloride, and *tris*-(hydroxymethyl)-aminomethane (Tris) hydrochloride from Sigma Chemicals (St. Louis, MO).

### D<sub>4</sub> Receptor Knockout Mice

Generation of D<sub>4</sub> receptor knockout mutant mice was detailed previously (Rubinstein et al., 1997). All mice tested were 8- to 10-week-old males F2s derived from the crossing of  $Drd4^{+/-}$  mice  $(129/Ola \times C57Bl/6J)$  for more than 10 generations (Rubenstein et al., 1997). Animals were housed in groups of five or six with free access to food and water and a 12/12-h light/dark cycle (lights on at 07.00 h). Age-matched wild-type and D<sub>4</sub> receptor knockout mice were killed by cervical dislocation, and their brains were rapidly removed and chilled on isopentane/dry ice. Brains were stored at -80°C in individual plastic vials until packed in dry ice in a Styrofoam box and mailed from Buenos Aires to Boston. All animal procedures were performed in accordance with the ethical standards set by the Guidelines for the Care and Use of Laboratory Animals of the United States Public Health Service.

### **Tissue Preparation**

Frozen sections (10  $\mu$ m) were prepared in a cryostat at -20°C, mounted on gelatin-coated, glass microscopic slides, and stored at -80°C until use. Coronal brain sections were taken through NAc septi, CPu, hippocampal regions CA<sub>1</sub> and CA<sub>3</sub>, and entorhinal cortex (EC), in which DA and Glu receptor subtypes are well expressed (Tarazi and Baldessarini, 1999b).

### Receptor Autoradiography

Brain sections from  $D_4$  receptor knockout mice and wild-type controls were evaluated at the same time in each radioreceptor assay to minimize experimental variability. Sections were first preincubated for 60 min at room temperature (RT) in specified assay buffers to remove endogenous ligands before incubating them with the radioligand.

### DA Receptor Autoradiography

### D<sub>1</sub> Receptors

Mouse forebrain sections were preincubated for 60 min at RT in 50 mM Tris-HCl buffer (pH 7.4) containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl<sub>2</sub>, and 1 mM MgCl<sub>2</sub>. Tissue sections were then incubated for 60 min at RT in the same buffer containing 1 nM

[ $^3$ H]SCH-23390 with 100 nM ketanserin to mask serotonin 5-HT $_{^{2A/2C}}$  receptors. Nonspecific binding was determined with excess (1  $\mu$ M) cis-flupenthixol. After incubation, slides were washed twice for 5 min in ice-cold buffer, dipped in ice-cold water, and dried under a stream of air (Florijn et al., 1997; Tarazi et al., 1997b, 2001). Though the resulting radioligand binding might include some binding to  $D_5$  sites, most of the signal is believed to represent  $D_1$  receptors.

### D<sub>2</sub> Receptors

Sections were incubated for 60 min at RT in the same buffer containing 1.0 nM [ $^3$ H]nemonapride with 0.5  $\mu$ M DTG and 0.1  $\mu$ M pindolol to mask  $\sigma_{1,2}$  and 5HT $_{1A}$  sites, respectively. Nonspecific binding was determined with 10  $\mu$ M S(–)-sulpiride. After incubation, slides were washed twice for 5 min in ice-cold buffer, dipped in ice-cold water, and airdried (Florijn et al., 1997; Tarazi et al., 1997b, 2001).

### D<sub>4</sub> Receptors

Assay methods are modified from those reported to quantify these receptors in rat brain (Tarazi et al., 1997a,b,2001). Tissue sections were preincubated for 60 min at RT in  $D_2$  assay buffer and then for another 60 min with 1.0 nM [ $^3$ H]nemonapride with 600 nM S(–)-raclopride to occupy  $D_2/D_3$  receptors optimally, as well as the masking agents (0.5  $\mu M$  DTG and 0.1  $\mu M$  pindolol) used in the  $D_2$  assay. Nonspecific binding was determined with 10  $\mu M$  S(–)-sulpiride.

### Glu Receptor Autoradiography

#### NMDA Receptors

Sections were preincubated for 60 min at RT in 50 mM Tris-HCl buffer (pH 7.4), then for 150 min at RT in fresh buffer containing  $10\,nM$  [ $^3$ H]MK-801, with  $100\,\mu$ M L-Glu,  $100\,\mu$ M glycine,  $1\,m$ M EDTA, and  $75\,\mu$ M spermine to enhance the binding of [ $^3$ H]MK-801 to its site within the open cation channels associated with NMDA receptors. Nonspecific binding was determined by including  $20\,\mu$ M ketamine. After incubation, slides were washed in icecold 50 mM Tris-HCl buffer, twice for 20 min, and dried (Tarazi et al., 1996, 1998, 2003).

### AMPA Receptors

Tissue sections were incubated for 60 min at RT in 50 mM Tris-HCl buffer (pH 7.2) and again for 60 min at RT in fresh buffer containing 30 nM [<sup>3</sup>H]AMPA with 2.5 mM CaCl<sub>2</sub> and 30 mM KSCN. Nonspecific binding was determined by including




Fig. 1. Sites of autoradiographic analyses of mouse brain regions sampled in 10- $\mu$ m coronal sections. NAc, nucleus accumbens septi; CPu, caudate putamen (L, lateral; M, medial); EC, entorhinal cortex; CA<sub>1</sub> and CA<sub>2</sub>, hippocampal regions.

30  $\mu$ M unlabeled CNQX. After incubation, slides were washed 3 times in ice-cold Tris buffer for 10 s and dried (Wullner et al., 1994; Tarazi et al., 2003).

### KA Receptors

Sections were preincubated for 60 min at 4°C in 50 mM Tris-HCl buffer (pH 7.0) and then incubated in this buffer containing 20 nM [ $^3$ H]KA for 60 min at 4°C. Nonspecific binding was determined with 25  $\mu$ M unlabeled KA. Slides were then washed 3 times in ice-cold 50 mM Tris buffer for 10 s and airdried (Tarazi et al., 1996, 1998, 2003).

# **Autoradiography and Image Analysis**

Radiolabeled slides and calibrated <sup>3</sup>H standards (Amersham) were exposed to Hyperfilm (Eastman-Kodak; Rochester, NY) at 4°C for 2–5 wk ([<sup>3</sup>H]SCH-23390 and [<sup>3</sup>H]nemonapride), 3 wk ([<sup>3</sup>H]AMPA and

[ $^3$ H]KA), or 4 wk ([ $^3$ H]MK-801). Films were developed in Kodak D-19 developer and fixative. Optical density (OD) in brain regions of interest (Fig. 1) was measured with a computerized densitometric image analyzer (MCID-M4, Imaging Research; St. Catharines, Ontario, Canada). Left and right sides of two contiguous sections represented total binding and two additional sections represented nonspecific binding; the four determinations were averaged for each of n = 6 subjects/treatment). Optical density was converted to nCi/mg of tissue using calibrated [ $^3$ H] standards and specific binding (total minus nonspecific binding) was expressed as fmol/mg tissue.

# **Data Analysis**

Effects of knocking out D<sub>4</sub> receptors on each receptor assay, by anatomical region, were tested by analy-

 $\label{eq:Table 1} \mbox{DA D}_4 \mbox{ Receptor Binding in Wild-Type and D}_4 \mbox{ Receptor Knockout Mice}$ 

	Mice	
Brain region	Wild type	D <sub>4</sub> receptor knockout
Nucleus accumbens	$38.4 \pm 1.0$	N.D.
Caudate putamen		
Medial part	$35.5 \pm 1.7$	N.D.
Lateral part	$60.3 \pm 1.8$	N.D.
Hippocampus		
$CA_1$ region	$17.3 \pm 1.1$	N.D.
CA <sub>3</sub> region	$17.5 \pm 0.9$	N.D.
Entorhinal cortex	$11.3 \pm 0.8$	N.D.

Data are mean  $\pm$  S.E.M. values for binding (fmol/mg tissue), determined by quantitative autoradiography (n = 6 rats/group; N.D., not detected), as described in Materials and Methods.

Brain region	Mice	
	Wild type	D <sub>4</sub> receptor knockout
Nucleus accumbens Caudate putamen	127.9 ± 4.7 (100)	$172.7 \pm 11.9 \ (135)^a$
Medial part Lateral part	$144.4 \pm 16.1 (100)$ $152.1 \pm 16.8 (100)$	$203.4 \pm 12.1 \ (141)^a$ $219.3 \pm 19.1 \ (144)^a$
Hippocampus		,
CA <sub>1</sub> region	$31.0 \pm 0.9 (100)$	$30.3 \pm 0.7 (98)$
CA <sub>3</sub> region Entorhinal cortex	$31.0 \pm 1.1 (100)$ $36.9 \pm 0.9 (100)$	$28.5 \pm 2.0 (92)$ $38.9 \pm 1.2 (105)$

Data are mean  $\pm$  S.E.M. values for binding (fmol/mg tissue and percent of control), determined by quantitative autoradiography with significant differences from controls indicated in boldface ( $^ap < 0.05$ ; n = 6 rats per group), as described in Materials and Methods.

sis of variance (ANOVA), with post hoc Dunnett t-tests used for planned comparisons of mutant vs wild-type mice, and considered significant at two-tailed p < 0.05. Data are presented as mean fmol/mg tissue  $\pm$  S.E.M. binding for n = 6 subjects per condition.

### Results

Autoradiographic analysis of tissue receptor levels under  $D_4$ -selective binding conditions detected a specific  $D_4$  signal (at 11–60 fmol/mg tissue) in different forebrain regions of wild-type control mice (Table 1). The highly  $D_4$ -selective ligands L-745,870 and RBI-257 (Kebabian et al., 1997), both at 1  $\mu$ M, displaced  $\geq$ 85% of binding remain-

ing in the presence of raclopride in CPu and NAc tissue from control mice, indicating that most of the raclopride-insensitive binding sites are  $D_4$  receptors. This specific signal was not detected in cerebral tissue sections of  $D_4$  receptor mutant mice, in which levels of total binding were indistinguishable from nonspecific binding in all forebrain regions examined (Table 1).

Distribution of DA  $D_1$  and  $D_2$  receptor labeling in mouse brain was similar to that found in rat brain (Tarazi et al., 1997b, 2001), with higher levels of  $D_1$  and  $D_2$  in NAc and CPu and lower levels in hippocampus and EC (Tables 2 and 3). In tissue from knockout mice vs controls, significant increases in  $D_1$  receptor binding were detected in NAc (by 35%)




Fig. 2. Autoradiographically determined density (gray scale indicated nCi/mg of [ $^3$ H]SCH23390 bound per mg tissue) of binding to D $_1$  receptors in CPu of wild-type mice (**A**) and D $_4$  receptor knockout mice (**B**). The results indicate significant increases in D $_1$  receptor binding in medial and lateral CPu of D $_4$  receptor mutant mice compared to wild-type controls.

and lateral (44%) and medial CPu (41%), but not in hippocampus or EC (Fig. 2; Table 2). In contrast, levels of  $D_2$  receptors did not differ between mutants and controls in any brain region examined (Table 3).

The observed distribution of ionotropic Glu receptors in mouse brain also accorded closely with our previous findings in rat brain (Tarazi et al., 1996, 1998). NMDA and AMPA receptors were highly expressed in hippocampal areas ( $CA_1 > CA_3$ ), followed by NAc and CPu (Tables 4 and 5). In contrast, KA receptors were expressed selectively in the hippocampal CA<sub>3</sub> region and Nac, followed by CPu (Table 6). A significant increase in binding at NMDA receptors also was observed in NAc (31%), lateral (44%) and medial CPu (41%), as well as in hippocampal CA<sub>1</sub> (21%) and CA<sub>3</sub> (25%) regions of D<sub>4</sub> mutants vs controls (Table 4). There were no significant differences in tissue concentrations of AMPA or KA receptors between D<sub>4</sub> mutant mice vs controls (Tables 5 and 6).

### **Discussion**

Autoradiographic quantification of  $D_4$  and  $D_2$  receptors in wild-type mice revealed that  $D_4$  receptors represented a relatively high proportion of  $D_2 + D_4$  receptors in mouse hippocampus (52–55%) and EC (40%–44%). In  $D_2$ -rich subcortical regions,  $D_4$  receptor levels were only 18% as high as  $D_2$  levels in NAc, and 15–19% in CPu (Tables 1 and 3). The observed proportional distribution of  $D_4/D_2$  recep-

tors in mouse brain accorded closely with another study that quantified D<sub>4</sub> receptor levels in mouse brain (Defagot et al., 2000) and with our previous findings on the proportional distribution of the same DA receptors in rat brain (Tarazi et al., 1997a). Transgenic mice lacking functional D<sub>4</sub> receptor genes showed total quantitative absence of  $D_{4}$  labeling receptors in comparison to wild-type mice in all brain regions examined (Table 1). In the current absence of D<sub>4</sub>-selective radioligands (Kula et al., 1999), these and other findings (Defagot et al., 2000) support our autoradiographic method to quantify D<sub>4</sub> receptors using [<sup>3</sup>H]nemonapride and optimal concentrations of cold S(-)-raclopride to occupy  $D_2/D_3$  and reveal  $D_4$  sites for selective labeling by [3H]nemonapride that were nearly completely occluded by the highly selective, unlabeled D₄ ligands L-745,870 and RBI-257.

Lack of expression of  $D_4$  receptors in mutant mice was associated with a significant increase in binding levels of DA  $D_1$  receptors in lateral and medial CPu (by 41–44%; Fig. 2; Table 2) and in NAc (35%; Table 2). A substantial proportion of striatal neurons that express  $D_1$  mRNA also coexpress  $D_4$  mRNA (Surmeier et al., 1996). The present findings suggest that  $D_1$  and  $D_4$  receptors might also be functionally associated, perhaps in the same or interacting neurons, so that genetically induced developmental loss of  $D_4$  receptors led to increased expression of  $D_1$  receptors in CPu and NAc (Fig. 2; Table 2). Physiological and behavioral implications of the hypoth-

Table 3 DA  $D_2$  Receptor Binding in Wild-Type and  $D_4$  Receptor Knockout Mice

Brain region	Mice	
	Wild type	D <sub>4</sub> receptor knockout
Nucleus accumbens Caudate putamen	$213.7 \pm 5.6 (100)$	$200.6 \pm 7.3 (94)$
Medial part Lateral part	$236.5 \pm 11.0 (100)$ $317.3 \pm 8.9 (100)$	$219.5 \pm 8.3 (93)$ $302.4 \pm 16.1 (95)$
Hippocampus $CA_1$ region $CA_3$ region	$33.3 \pm 2.7 (100)$ $31.8 \pm 1.5 (100)$	$34.6 \pm 1.1 (104)$ $28.7 \pm 2.4 (90)$
Entorhinal cortex	$25.6 \pm 1.0 (100)$	$26.0 \pm 1.5 (102)$

Data are mean  $\pm$  S.E.M. values for binding (fmol/mg tissue and percent of control), determined by quantitative autoradiography (n = 6 rats per group), as described in Materials and Methods. No difference is statistically significant.

 $\label{eq:Table 4} \mbox{NMDA Receptor Binding in Wild-Type and $D_4$ Receptor Knockout Mice}$ 

Brain region	Mice	
	Wild type	D <sub>4</sub> receptor knockout
Nucleus accumbens Caudate putamen	315.3 ± 21.8 (100)	$413.2 \pm 22.0 \ (131)^a$
Medial part Lateral part	$287.7 \pm 13.0 (100)$ $330.9 \pm 21.1 (100)$	$406.1 \pm 19.2  (141)^a$ $463.2 \pm 26.7  (140)^a$
Hippocampus $CA_1$ region $CA_3$ region Entorhinal cortex	$625.6 \pm 22.7 (100)$ $372.7 \pm 31.2 (100)$ $184.7 \pm 18.0 (100)$	$758.8 \pm 20.1$ (121) <sup>a</sup> $464.0 \pm 21.2$ (125) <sup>a</sup> $174.6 \pm 16.5$ (95)

Data are mean  $\pm$  S.E.M. values for binding (fmol/mg tissue and percent of control), determined by quantitative autoradiography, with significant differences from controls indicated in boldface ("p < 0.05; n = 6 rats per group), all as described in Materials and Methods.

esized functional interaction of  $D_1/D_4$  receptors remain to be determined. However, based on the molecular similarities of  $D_4$  and  $D_2$  receptors (Baldessarini and Tarazi, 1996) and evidence of functional synergism between  $D_2$  and  $D_1$  receptors (Hu and White, 1994; Keefe and Gerfen, 1995), it seems plausible that  $D_4$  and  $D_1$  receptors also might interact functionally. In addition, the observed increase in  $D_1$  receptor binding might contribute to the reported supersensitive locomotor responses to psychostimulants in  $D_4$  receptor knockout mice (Rubinstein et al., 1997).

Interestingly, levels of  $D_2$  receptors remained unchanged in forebrain regions of  $D_4$ -receptor knockout mice compared to wild-type controls (Table 3). We reported previously that  $D_1$ ,  $D_2$ , and  $D_4$  receptors all follow a similar pattern of postnatal development in several forebrain regions (Tarazi and Baldessarini, 2000). Our present findings suggest further that  $D_1$  and  $D_4$  receptors, but not  $D_2$  receptors, are developmentally linked, in that  $D_1$  expression selectively increased in association with a profound ontogenetic loss of cerebral  $D_4$  receptors. It will be interesting to determine if the  $D_1/D_4$  developmental control of the profound of the profound

Table 5
AMPA Receptor Binding in Wild-Type and D <sub>4</sub> Receptor Knockout Mice

Brain region	Mice	
	Wild type	D <sub>4</sub> receptor knockout
Nucleus accumbens Caudate putamen	364.4 ± 11.9 (100)	372.2 ± 16.7 (102)
Medial part Lateral part	$235.0 \pm 15.2 (100)$ $251.9 \pm 16.2 (100)$	$237.7 \pm 15.8 (101)$ $252.6 \pm 17.9 (100)$
Hippocampus CA <sub>1</sub> region CA <sub>3</sub> region Entorhinal cortex	$485.3 \pm 17.9 (100)$ $368.9 \pm 17.5 (100)$ $346.7 \pm 17.4 (100)$	$476.5 \pm 10.8 (98)$ $388.5 \pm 15.2 (105)$ $367.7 \pm 11.2 (106)$

Data are mean  $\pm$  S.E.M. values for binding (fmol/mg tissue and percent of control), determined by quantitative autoradiography (n = 6 rats per group), as described in Materials and Methods. No difference is statistically significant.

Table 6 KA Receptor Binding in Wild-Type and D<sub>4</sub> Receptor Knockout Mice

Brain region	Mice	
	Wild type	D <sub>4</sub> receptor knockout
Nucleus accumbens Caudate putamen	192.3 ± 11.4 (100)	196.0 ± 7.8 (102)
Medial part Lateral part	$133.4 \pm 3.4 (100)$ $152.8 \pm 4.8 (100)$	$125.5 \pm 3.7 (94)$ $147.0 \pm 5.1 (96)$
Hippocampus CA <sub>1</sub> region CA <sub>3</sub> region	$84.4 \pm 2.7 (100)$ $202.7 \pm 7.9 (100)$	88.9 ± 2.9 (105) 211.5 ± 8.6 (104)
Entorhinal cortex	$163.4 \pm 6.4 (100)$	$154.5 \pm 5.9 (95)$

Data are mean  $\pm$  S.E.M. values for binding (fmol/mg tissue and percent of control), determined by quantitative autoradiography (n = 6 rats per group), as described in Materials and Methods. No difference is statistically significant.

opmental link is reciprocal and if genetic loss of  $D_1$  receptors leads to increased expression of  $D_4$  receptors.

Effects of genetically halting the expression of D<sub>4</sub> receptors included significant increases in Glu NMDA receptors in NAc and CPu of D<sub>4</sub> receptor mutants compared to wild-type controls (Table 4). We previously reported that D<sub>4</sub> heteroceptors seem to co-localize with presynaptic NMDA autoreceptors on the same or parallel corticostriatal fibers innervating CPu and NAc, suggesting that D<sub>4</sub> (inhibitory) and NMDA (excitatory) receptors might play opposite roles in controlling release of Glu in these subcortical brain regions (Tarazi et al., 1998, Tarazi and Baldessarini, 1999b). The observed increases in NMDA receptors in CPu and NAc might reflect neuronal adaptation to compensate for the

loss of  $D_4$  receptors in mutant mice. In agreement with the reported increased excitability of glutamatergic neurons in cerebral cortex of  $D_4$  receptor-deficient mice (Rubinstein et al., 2001), the domination of NMDA receptors on terminals of corticostriatal projections might also increase excitability of glutamatergic neurons innervating CPu and NAc.

Functional interaction and perhaps colocalization of  $D_4$  and NMDA receptors are not limited to CPu and NAc but evidently also extend to the hippocampal formation, as significant increases in NMDA receptor binding were detected in hippocampal  $CA_1$  and  $CA_3$  regions of  $D_4$  receptor-deficient mice vs. controls (Table 4). A recent study provides evidence for  $D_4$ /NMDA receptor functional interactions in the hippocampus, in that stimulation

of D<sub>4</sub> receptors inhibited NMDA-evoked currents in hippocampal CA<sub>1</sub> neurons, reportedly mediated by transactivation of receptor tyrosine kinases (Kotecha et al., 2002). These observations suggest that D<sub>4</sub> receptors act as inhibitory modulators of excitatory neuronal activity in the hippocampus. Therefore, the absence of D₄ receptors, together with the observed increase in hippocampal NMDA receptors in D<sub>4</sub> receptor mutant mice, suggests that a state of hyperglutamatergic excitability might occur in hippocampal neurons of these genetically altered mice. This hypothesis remains to be tested experimentally. AMPA and KA receptors are less likely to interact developmentally or functionally with D<sub>4</sub> receptors, as tissue levels of both of these ionotropic Glu receptor subtypes did not differ significantly between D<sub>4</sub> knockouts and their controls (Tables 5 and 6).

Altogether, the present findings suggest that novel functional interactions occur between a trio of DA and Glu receptors—D<sub>1</sub>, D<sub>4</sub>, and NMDA particularly in the corpus striatum. A functional interaction has been reported for D<sub>1</sub> and NMDA receptors. For example, NMDA receptor activation reversed D<sub>1</sub>/cAMP-stimulated phosphorylation of DARPP-32 (dopamine and cAMP-regulated phosphoprotein of molecular mass 32K) in striatal brain slices (Halpain et al., 1990), whereas stimulation of D<sub>1</sub> receptors enhanced NMDA-evoked responses (Flores-Hernandez et al., 2002). Similarly, administration of the noncompetitive NMDA receptor antagonist MK-801 limited increases of striatal acetylcholine produced by D<sub>1</sub> receptor agonists (Damsma et al., 1991) and prevented D<sub>1</sub>-mediated increases in rat striatal neurotensin levels following methamphetamine treatment (Singh et al., 1990). It is tempting to speculate that D₄ receptors play a pivotal regulatory role in mediating the functional interactions between D<sub>1</sub> and NMDA receptors. Therefore, genetic manipulations that knock out expression of D<sub>4</sub> receptors are hypothesized also to disrupt D<sub>1</sub>/NMDA interactions, lead to an increased expression of striatal D<sub>1</sub> and NMDA receptors, and subsequently alter signal transduction mechanisms and cellular responses linked to D<sub>1</sub> and NMDA receptors.

In conclusion, generation of  $D_4$  receptor mutant mice has advanced knowledge of functions and behaviors presumably mediated by  $D_4$  receptors. However, molecular mechanisms and neural pathways that underlie behavioral changes reported in  $D_4$  receptor knockout mice might not be influenced solely by their lack of  $D_4$  receptors, as apparent sec-

ondary changes were also found in these mutant mice, including increased expression of DAD $_1$  receptors in NAc and CPu, and NMDA receptors in NAc, CPu, and hippocampus. These presumably reactive or compensatory developmental changes in D $_1$  and NMDA receptors might also contribute to the altered functions and behaviors observed in D $_4$  receptor knockout mice. In general, our findings indicate the need for cautious interpretation of targeted knockout of specific receptor genes in mice, as complex adaptive changes involving other receptor subtypes and/or neurotransmitter systems directly or indirectly related to the missing gene might contribute to physiological and behavioral responses of such mutants.

## Acknowledgments

This work was supported by the Stanley Medical Research Institute and a NARSAD Young Investigator Award (F. I. T.), an Adam Corneel Award (K. Z.), a grant from the Bruce J. Anderson Foundation, and funds from the McLean Hospital Private Donors Neuropharmacology Research Fund (R. J. B.), ANPCYT (PICT 5-5362; M. R.), UBACYT 2001-2003 (M. R.), and the HHMI (M. R.).

#### References

Ariano M. A., Wang J., Noblett K. L., Larson E. R., and Sibley D. R. (1997) Cellular distribution of the rat D<sub>4</sub> dopamine receptor protein in the CNS using anti-receptor antisera. *Brain Res.* **752**, 26–34.

Baldessarini R. J. and Tarazi F. I. (1996) Brain dopamine receptors: A primer on their current status, basic and clinical. *Harvard Rev. Psychiatry* **3**, 301–325.

Benjamin J., Li L., Patterson C., Greenberg B. D., Murphy D. L., and Hamer D. H. (1996) Population and familial association between  $D_4$  dopamine receptor gene and measures of novelty-seeking. *Nat. Genet.* 12, 81–84.

Bucan M. and Abel T. (2002) The mouse: genetics meets behavior. *Nat. Rev. Genet.* **3**, 114–123.

Carlsson M. and Carlsson A. (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. *Trends Neurosci.* **13**, 272–276.

Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., and Carlsson M.L. (2001) Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. *Ann. Rev. Pharmacol. Toxicol.* **41**, 237–260.

Damsma G., Robertson G. S., Tham C. S., and Fibiger H. C. (1991) Dopaminergic regulation of striatal acetylcholine release: importance of D<sub>1</sub> and N-methyl-D-aspartate receptors. *J. Pharmacol. Exp. Ther.* **259**, 1064–1072.

- Defagot M. C., Falzone T. L., Low M. J., Grandy D. K., Rubinstein M., and Antonelli M. C. (2000) Quantitative analysis of the dopamine D<sub>4</sub> receptor in the mouse brain. *J. Neurosci. Res.* **59**, 202–208.
- Defagot M. C., Malchiodi E. L., Villar M. J., and Antonelli M. C. (1997) Distribution of D<sub>4</sub> dopamine receptor in rat brain with sequence-specific antibodies. *Mol. Brain Res.* **45**, 1–12.
- Dulawa S. C., Grandy D. K., Low M. J., Paulus M. P., and Geyer M. A. (1999) Dopamine D<sub>4</sub> receptor-knock-out mice exhibit reduced exploration of novel stimuli. *J. Neurosci.* **19**, 9550–9556.
- Ebstein R. P., Novik O., Umansky R., Priel B., Osher Y., Blaine D., et al. (1996) Dopamine D<sub>4</sub> receptor (D4DR) exon III polymorphism associated with the human personality trait of novelty seeking. *Nat. Genet.* **12**, 78–80.
- Falzone T. L., Gelman D. M., Young J. I., Grandy D. K., Low M. J., and Rubinstein M. (2002) Absence of dopamine D<sub>4</sub> receptors results in enhanced reactivity to unconditioned, but not conditioned, fear. *Eur. J. Neurosci.* **15**, 158–164.
- Flores-Hernandez J., Cepeda C., Hernandez-Echeagaray E., Calvert C. R., Jokel E. S., Fienberg A. A., et al. (2002) Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D<sub>1</sub> receptors and DARPP-32. *J. Neurophysiol.* **88**, 3010–3020.
- Florijn W. J., Tarazi F.I., and Creese I. (1997) Dopamine receptor subtypes: differential regulation following 8 months treatment with antipsychotic drugs. *J. Pharmacol. Exp. Ther.* **280**, 561–569.
- Halpain S., Girault J. A., and Greengard P. (1990) Activation of NMDA receptors induce dephosphorylaton of DARPP-32 in rat striatal slices. *Nature* **343**, 369–372.
- Hu X. T. and White F. J. (1994) Loss of  $D_1/D_2$  dopamine receptor synergisms following repeated administration of  $D_1$  or  $D_2$  receptor selective antagonists: electrophysiological and behavioral studies. *Synapse* **17**, 43–61.
- Kebabian J. W., Tarazi F. I., Kula N. S., and Baldessarini R. J. (1997) Compounds selective for dopamine receptor subtypes. *Drug Discovery Today* **2**, 333–340.
- Keefe K. A. and Gerfen C. R. (1995) D<sub>1</sub>-D<sub>2</sub> dopamine receptor synergy in striatum: effects of intrastriatal infusions of dopamine agonists and antagonists on immediate early gene expression. *Neuroscience* **66**, 903–113.
- Kotecha S. A., Oak J. N., Jackson M. F., Perez Y., Orser B. A., Van Tol H. H. M., and MacDonald J. F. (2002) A  $D_2$  class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission. *Neuron* **35**, 1111–1122.
- Kula N. S., Tarazi F. I., Baldessarini R. J., Xu L., Bakthavachalam V., Pounds S., and True C. D. (1999) Neuropharmacological assessment of potential dopamine  $D_4$ -selective radioligands. *Eur. J. Pharmacol.* **367**, 139–142
- La Hoste G. J., Swanson J. M., Wigal S. B., Glabe C., Wigal T., King N., and Kennedy J. L. (1996) Dopamine D<sub>4</sub> receptor gene polymorphism is associated with attention deficit hyperactivity disorder. *Mol. Psychiatry* **1**, 128–131.

Lichter J. B., Barr C. L., Kennedy J. L., Van Tol H. H. M., Kidd K. K., and Livak K. J. (1993) A hypervariable segment in the human dopamine receptor  $D_4$  (DRD4) gene. *Hum. Mol. Genet.* **6,** 767–773.

- Mrzljak L., Bergson C., Pappy M., Huff R., Levenson R., and Goldman-Rakic P. S. (1996) Localization of dopamine D<sub>4</sub> receptors in GABAergic neurons of the primate brain. *Nature* **381**, 245–248.
- Neve K. A. and Neve R. L. (1997) *The Dopamine Receptors*, Humana Press, Totowa, NJ.
- Rubinstein M., Cepeda C., Hurst R. S., Flores-Hernandez J., Ariano M. A., Falzone T., et al. (2001) Dopamine D<sub>4</sub> receptor-deficient mice display cortical hyperexcitability. *J. Neurosci.* **21**, 3756–3763.
- Rubinstein M., Phillips T. J., Bunzow J. R., Falzone T. L., Dziewczapolski G., Zhang G., et al. (1997) Mice lacking dopamine  $D_4$  receptors are supersensitive to ethanol, cocaine, and methamphetamine. *Cell* **90**, 991–1001.
- Singh N. A., Bush L. G., Gibb J. W., and Hanson G. R. (1990) Dopamine-mediated changes in central nervous system neurotensin systems: a role for NMDA receptors. *Eur. J. Pharmacol.* **187**, 337–344.
- Surmeier D. J., Song W. J., and Yan Z. (1996) Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. *J. Neurosci.* **16**, 6579–6591.
- Swanson J. M., Sunahara G. A., Kennedy J. L., Regino R., Fineberg E., Wigal T., et al. (1998) Association of the dopamine receptor D<sub>4</sub> (DRD4) gene with a refined phenotype of attention deficit hyperactivity disorder (ADHD). *Mol. Psychiatry* **3**, 38–41.
- Tarazi F. I. and Baldessarini R. J. (1999a) Dopamine D<sub>4</sub> receptors: significance for molecular psychiatry at the millennium. *Mol. Psychiatry* **4**, 529–538.
- Tarazi F. I. and Baldessarini R. J. (1999b) Regional localization of dopamine and glutamate receptor subtypes in striatolimbic brain regions. *J. Neurosci. Res.* **55**, 401–410.
- Tarazi F. I. and Baldessarini R. J. (2000) Comparative postnatal development of dopamine  $D_1$ ,  $D_2$  and  $D_4$  receptors in rat forebrain. *Int. J. Dev. Neurosci.* **18**, 29–37.
- Tarazi F. I., Baldessarini R. J., Kula N. S., and Zhang K. (2003) Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: Implications for antipsychotic drug treatment. *J. Pharmacol. Exp. Ther.* **306**, 1145–1151.
- Tarazi F. I., Campbell A., Yeghiayan S. K., and Baldessarini R. J. (1998) Localization of glutamate receptor subtypes in caudate-putamen and nucleus accumbens septi: Comparison of NMDA, AMPA and kainate receptors. *Synapse* **30**, 227–235.
- Tarazi F. I., Florijn W. J., and Creese I. (1996) Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. *Psychopharmacology* **128**, 371–379.
- Tarazi F. I., Kula N. S., and Baldessarini R. J. (1997a) Regional distribution of dopamine D<sub>4</sub> receptors in rat forebrain. *NeuroReport* 8, 3423–3426.

- Tarazi F. I., Yeghiayan S. K., Baldessarini R. J., Kula N. S., and Neumeyer J. L. (1997b) Long-term effects of S(+)N-n-propylnorapomorphine compared with typical and atypical antipsychotics: Differential increases of cerebrocortical  $D_2$ -like and striatolimbic  $D_4$ -like dopamine receptors. *Neuropsychopharmacology* **17**, 186–196.
- Tarazi F. I., Zhang K., and Baldessarini R. J. (2001) Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: Implications for antipsychotic drug treatment. *J. Pharmacol. Exp. Ther.* **297**, 711–717.
- Van Tol H. H. M., Bunzow J. R., Guan H.-C., Sunahara R. K., Seeman P., Niznik H. B., and Civelli O. (1991) Cloning of a human dopamine  $D_4$  receptor gene with high affinity for the antipsychotic clozapine. *Nature* **350**, 614–619.

- Van Tol H. H. M., Wu C. M., Guan H.-C., Ohara K., Bunzow J. R., Civelli O., et al. (1992) Multiple dopamine D<sub>4</sub> receptor variants in the human population. *Nature* **358**, 149–152.
- Wullner U., Testa C.M., Catania M. V., Young A. B., and Penney J. B. (1994) Glutamate receptors in striatum and substantia nigra: Effects of medial forebrain bundle lesions. *Brain Res.* **645**, 98–102.
- Zhang K., Davids E., Tarazi F. I., and Baldessarini R. J. (2002) Effects of dopamine D<sub>4</sub> receptor-selective antagonists on motor hyperactivity in rats with neonatal 6-hydroxydopamine lesions. *Psychopharmacology* **161**, 100–106.
- Zhang K., Tarazi F. I., and Baldessarini R. J. (2001) Role of dopamine D<sub>4</sub> receptors in motor hyperactivity induced by neonatal 6-hydroxydopamine lesions in rats. *Neuropsychopharmacology* **25**, 624–632.